Prot #GLPG1690: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects with Idiopathic P

  • Tomic, Rade (PD/PI)

Project: Research project

Project Details

StatusActive
Effective start/end date8/8/1910/29/25

Funding

  • PPD Investigator Services, LLC ((OE) Prot #GLPG1690 // (OE) Prot #GLPG1690)
  • Galapagos NV ((OE) Prot #GLPG1690 // (OE) Prot #GLPG1690)